Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

CDCP1+ mesenchymal stem cells preferentially inhibit acute graft-versus-host disease(aGVHD)

View Full Paper
Ask AI
Bookmark
Share

Authors

LYLun Yan

Discussion

Loading...

Member takes

Overview

Single-cell sequencing reveals that CDCP1+ MSCs enhance Treg differentiation in preventing acute graft-versus-host disease, suggesting their therapeutic potential.

Key Points

  • The research investigates the role of CDCP1+ mesenchymal stem cells in preventing acute graft-versus-host disease (aGVHD).
  • Single-cell sequencing identified CDCP1+ MSCs.
  • Flow cytometry was used to sort CDCP1+ MSCs.
  • T cell proliferation was analyzed using CCK-8 and CSFE assays.
  • Cytokine release was assessed by ELISA.
  • Gene expression changes were evaluated through transcriptome sequencing.
  • CDCP1+ MSCs significantly inhibited T cell proliferation compared to knockdown counterparts.
  • Increased Treg cell numbers were noted with CDCP1+ MSCs, while Th2, Th17, Tc1, Tc2, and Tc17 cells decreased.
  • Release of cytokines TNF-α, IL-4, IL-6, and IL-21 was lower in CDCP1+ MSCs group.
  • Migration ability of CDCP1+ MSCs was stronger, reduced after CDCP1 knockdown.
  • Down-regulation of gene CDKN2B highlighted as significant after CDCP1 knockdown.

Cite This Study

Lun Yan (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e1a3https://doi.org/10.1182/blood-2025-2466
View Full Paper
Ask AI
Bookmark
Share